Skip to main content
Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,208.12
+80.43 (7.13%)
At close: Jun 26, 2026, 4:00 PM EDT
1,211.00
+2.88 (0.24%)
After-hours: Jun 26, 2026, 7:59 PM EDT

Eli Lilly Revenue by Segment
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Cardiometabolic
54.77B 48.22B 42.84B 37.06B 33.24B 29.52B 26.16B 23.47B
Cardiometabolic Growth
64.80% 63.35% 63.74% 57.90% 58.49% 50.10% 46.17% 39.40%
Oncology
9.70B 9.38B 9.32B 9.14B 8.89B 8.75B 8.08B 7.60B
Oncology Growth
9.07% 7.12% 15.29% 20.33% 24.99% 31.45% 25.83% 27.27%
Immunology
5.36B 5.25B 5.00B 4.82B 4.65B 4.39B 4.21B 4.01B
Immunology Growth
15.39% 19.44% 18.79% 20.28% 20.59% 15.68% 15.98% 14.30%
Neuroscience
1.50B 1.39B 1.32B 1.36B 1.36B 1.47B 1.44B 2.86B
Neuroscience Growth
10.65% -5.60% -8.19% -52.40% -53.34% -48.81% -50.26% 89.84%
Other
917.10M 943.00M 942.20M 867.80M 873.90M 902.90M 968.50M 981.80M
Other Growth
4.94% 4.44% -2.72% -11.61% -19.74% -19.54% -20.74% -41.97%

Revenue by Geography
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
United States
47.11B 43.48B 39.64B 36.15B 33.17B 30.38B 27.80B 25.35B
United States Growth
42.03% 43.15% 42.58% 42.58% 43.91% 39.39% 39.03% 33.10%
Europe
12.82B 11.56B 10.91B 9.04B 7.87B 6.92B 5.81B 6.75B
Europe Growth
62.85% 67.01% 87.76% 33.91% 20.61% 12.08% -1.71% 53.44%
Rest of World
7.83B 6.06B 4.93B 4.35B 4.38B 4.27B 3.95B 3.62B
Rest of World Growth
78.98% 41.81% 24.78% 20.08% 38.20% 44.97% 30.64% 25.97%
Japan
2.30B 2.13B 2.04B 1.91B 1.85B 1.81B 1.69B 1.66B
Japan Growth
24.19% 17.48% 20.18% 15.38% 12.34% 8.50% 4.06% -4.00%
China
2.19B 1.95B 1.91B 1.81B 1.74B 1.66B 1.61B 1.54B
China Growth
26.40% 17.52% 18.52% 17.31% 12.43% 7.83% 6.28% 5.01%

Operating Expense Breakdown
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Research and Development
14.11B 13.34B 12.56B 11.83B 11.20B 10.99B 10.53B 10.21B
Research and Development Growth
25.99% 21.35% 19.25% 15.88% 13.71% 18.01% 20.40% 25.37%
Marketing, Selling, and Administrative
11.56B 11.09B 10.39B 9.75B 9.11B 8.59B 8.09B 7.80B
Marketing, Selling, and Administrative Growth
26.88% 29.09% 28.33% 24.98% 19.78% 16.08% 13.65% 12.49%
Acquired In-Process Research and Development
1.92B 2.91B 2.57B 4.74B 4.74B 3.28B 3.71B 3.86B
Acquired In-Process Research and Development Growth
-59.46% -11.29% -30.79% 22.75% 24.61% -13.67% 8.68% 665.46%
Impairment, Restructuring, and Other
728.00M 484.00M 743.90M 460.60M 895.60M 860.60M 523.37M 441.77M
Impairment, Restructuring, and Other Growth
-18.71% -43.76% 42.14% 4.26% 13,128.95% 12,611.96% 1,273.67% 80.61%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.